Pardanani A - Search Results

1

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes.

Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA, Tefferi A. Pardanani A, et al. Leukemia. 2012 Apr;26(4):693-9. doi: 10.1038/leu.2011.251. Epub 2011 Sep 13. Leukemia. 2012. PMID: 21912394 Free PMC article.

2

Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.

Baek JY, Tefferi A, Pardanani A, Li CY. Baek JY, et al. Among authors: pardanani a. Leuk Res. 2002 Jan;26(1):83-90. doi: 10.1016/s0145-2126(01)00102-3. Leuk Res. 2002. PMID: 11734306

3

Bone marrow angiogenesis in systemic mast cell disease.

Baek JY, Li CY, Pardanani A, Butterfield JH, Tefferi A. Baek JY, et al. Among authors: pardanani a. J Hematother Stem Cell Res. 2002 Feb;11(1):139-46. doi: 10.1089/152581602753448603. J Hematother Stem Cell Res. 2002. PMID: 11847010

4

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.

Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Tefferi A, et al. Among authors: pardanani a. Blood. 2002 May 15;99(10):3854-6. doi: 10.1182/blood-2001-12-0154. Blood. 2002. PMID: 11986248 Free article. Clinical Trial.

5

Treatment of hypereosinophilic syndrome with imatinib mesilate.

Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Gleich GJ, et al. Among authors: pardanani a. Lancet. 2002 May 4;359(9317):1577-8. doi: 10.1016/S0140-6736(02)08505-7. Lancet. 2002. PMID: 12047970

6

Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study.

Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Pardanani A, et al. Mayo Clin Proc. 2002 Nov;77(11):1169-75. doi: 10.4065/77.11.1169. Mayo Clin Proc. 2002. PMID: 12440552

7

Primer on medical genomics. Part IV: Expression proteomics.

Pardanani A, Wieben ED, Spelsberg TC, Tefferi A. Pardanani A, et al. Mayo Clin Proc. 2002 Nov;77(11):1185-96. doi: 10.4065/77.11.1185. Mayo Clin Proc. 2002. PMID: 12440555 Review.

8

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.

Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Pardanani A, et al. Blood. 2003 May 1;101(9):3391-7. doi: 10.1182/blood-2002-10-3103. Epub 2002 Dec 27. Blood. 2003. PMID: 12506022 Free article.

9

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. Mesa RA, et al. Among authors: pardanani a. Blood. 2003 Apr 1;101(7):2534-41. doi: 10.1182/blood-2002-09-2928. Epub 2002 Nov 27. Blood. 2003. PMID: 12517815 Free article. Clinical Trial.

10

Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder.

Pardanani A, Kimlinger TK, Reeder TL, Li CY, Tefferi A. Pardanani A, et al. Br J Haematol. 2003 Feb;120(4):691-4. doi: 10.1046/j.1365-2141.2003.04125.x. Br J Haematol. 2003. PMID: 12588358 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

460 results

Search Page

Filters